Board of Directors
Carol Wallace, MD (Chair)
Dr. Wallace received her MD from the University of Michigan in 1973. She completed both her residency in pediatrics and fellowship in pediatric rheumatology at the University of Washington. Following this, she was in private practice pediatrics and rheumatology until she joined the University of Washington and Children’s Hospital and Regional Medical Center in 1984. Dr. Wallace’s main focus has been the aggressive treatment of Juvenile Idiopathic Arthritis (JIA) and other Pediatric Rheumatic Diseases. She has published many of the sentinel studies of the use of methotrexate in the treatment of JIA.
Elizabeth Mellins, MD
Professor of Pediatrics
Dr. Mellins’ lab focuses on the study of antigen presentation by major histocompatibility complex (MHC) class II molecules. She has been particularly interested in the molecular mechanisms and intracellular steps involved in the generation of complexes between MHC class II molecules and peptides. Her basic work in this area has elucidated the roles of invariant chain and HLA-DM, two molecules which regulate peptide-loading of class II molecules. She continues to study basic molecular mechanisms in antigen presentation by MHC class II molecules, focusing now on particular events in antigen presentation by B cells. In addition, the lab has an active program to understand the molecular basis of class II associations with autoimmune diseases.
Christy Sandborg, MD
Professor of Pediatrics
The major emphasis of Dr. Sandborg’s work in the past decade has been focused on the future of academic pediatrics and pediatric rheumatology through providing training, research opportunities and environments to nurture and challenge future pediatric rheumatologists and subspecialists, and has now expanded to encompass design of new models of care for children with complex chronic illness.
Yukiko Kimura, MD Chief, Division of Pediatric Rheumatology and Professor of Pediatrics at Joseph M. Sanzari Children’s Hospital, Hackensack University Medical Center
Dr. Kimura is the chief of the Division of Pediatric Rheumatology at the Children’s Hospital at Hackensack University Medical Center, and Professor of Pediatrics at Rutgers New Jersey Medical School. Her research efforts have been directed toward improving the health, treatment and outcomes for patients with JIA and other pediatric rheumatic diseases. She is the current Chair of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), President of CARRA, Inc. and co-Principal Investigator (PI) of the CARRA Registry, which is studying the long-term safety of medications being used to treat JIA. Dr Kimura led the development of the CARRA consensus treatment plans (CTPs) for both systemic JIA and polyarticular JIA, which are now being implemented through CARRA Registry-wide comparative effectiveness studies.
Brian Kotzin, MD
Brian Kotzin, MD completed his medical education at Stanford University and residency in internal medicine at the Beth Israel Hospital (Harvard) in Boston Massachusetts. He completed his rheumatology fellowship in the Division of Rheumatology and Immunology at Stanford University Medical Center. His ~25 year academic career included major commitments to patient care, research, and teaching. Interest in clinical research to develop novel therapeutics for rheumatic diseases resulted in Dr. Kotzin joining Amgen Inc. in Thousand Oaks California in 2004 as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area. Positions at Amgen also included Vice President and Head of Medical Sciences, an integrated department comprised of Early Clinical Development, Molecular Sciences, Imaging Sciences, Clinical Immunology, and Computational Biology.
Leigh White, JD
Executive Vice President
Leigh White is Executive Vice President at CurAgeis Technologies, responsible for building the company’s fatigue management division around new leading edge scientific technology. She joined CurAegis (pronounced like “courageous”) in September 2015 after 6 years as President of Alertness Solutions – a leading fatigue management firm with significant focus on the aviation industry.
Prior to acquiring Alertness Solutions, she spent 14 years as a Silicon Valley venture capital investor. Ms. White holds a Bachelors Degree in Finance from Wichita State University. She earned her J.D. from Stanford Law School in 1996 and is a member of the State Bar of California.
Harry Saal, PhD
Dr. Harry J. Saal was the founder and CEO of Network General Corporation, the first company wholly dedicated to the area of network diagnostics and the creator of the eponymous "Sniffer" network analyzer. In 2002, Dr. Saal was chosen by the US Department of Justice to lead the Technical Committee charged with monitoring and enforcing the Microsoft Antitrust case. He served as Chairman of the Committee through the May 2011 expiration of the Judgment.
Most recently, he is the Chair of Retrotope, Inc. a pharmaceutical startup, based here in Silicon Valley. Dr. Saal is confident that the compounds under development stand an excellent chance of revolutionizing the treatment and prevention of a wide variety of untreatable neurodegenerative diseases of aging.